A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years

Completed · Phase 1

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if 2 study vaccines, ALVAC-HIV (vCP1452) and gp160 MN/LAI-2, are safe and effective in boosting the body's attacks on HIV in HIV-positive patients. HIV-infected patients who have been treated with anti-HIV drugs for a long time may have weakened immune responses. One way to strengthen these responses may be to have a safe and effective vaccine, which will boost immune responses that are specific to HIV.

Key facts

Study ID

NCT00006509

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

12

Expected to finish

2007-06-01

Last updated by the study team

2015-03-09

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients may be eligible for this study if they:
• Are HIV-positive.
• Have a viral load (amount of HIV in the blood) of less than 50 copies/ml.
• Have been taking anti-HIV drugs for at least 2 years.
• Are already participating in ongoing clinical trials at the Aaron Diamond AIDS Research Center.
• Are at least 19 years old.
• Practice abstinence or use 2 barrier methods of birth control, both men and women who are able to have children.

You may not qualify if…

• Patients will not be eligible for this study if they:
• Have HIV infection that is spreading through the body even though they are taking anti-HIV drugs.
• Are breast-feeding.
• Are pregnant.
• Are allergic to eggs and/or neomycin.
• Show evidence of poor immune responses.

Where it is running

• Aaron Diamond AIDS Res Ctr — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.